This discrepancy was not observed in our subsequent experiments, where our boosting strategy with serologically distinct recombinant virus, led to a further improvement in the protection against leishmaniasis and increased longevity of IFN-γ responses. This evidence concerns the gene IFNG and leishmaniasis.